¸ð½Ã´Â±Û ÇÁ·Î±×·¥ ÃÊ·ÏÁ¢¼ö »çÀüµî·Ï ¹ßÇ¥ÀÚ ¾È³» ¼ö»óÀÚ ¾È³» Çà»çÀå¾È³» ¼÷¹Ú¾È³» Ȩ
 ÀϹݿ¬Á¦ ¹ßÇ¥ ¾È³»

  1. ¹ßÇ¥½Ã°£ ¹× ¹ßÇ¥Àå¼Ò : Çмú´ëȸ ȨÆäÀÌÁö ¡®¹ßÇ¥ÀÚ ¾È³»¡¯¿¡¼­ È®ÀÎ
  2. ¹ßÇ¥½½¶óÀ̵å Á¦Ãâ : 2015³â 9¿ù 14ÀÏ(¿ù)±îÁö office@ksog.org·Î Á¦Ãâ(PPTÆÄÀÏ)
    ¹ßÇ¥½½¶óÀ̵å´Â »çÀü¿¡ ¹Ýµå½Ã Á¦ÃâÇÏ¿©¾ß Çϸç, ¹ßÇ¥ ´çÀÏ ¼öÁ¤µÈ ÆÄÀÏ·Î ±³Ã¼°¡´ÉÇÔ
    (¹ßÇ¥½½¶óÀÌµå ¹ÌÁ¦Ãâ½Ã ¹ßÇ¥Æ÷±â·Î °£ÁÖÇÔ)
  3. ¹ßÇ¥°ü·Ã À¯ÀÇ»çÇ×
    - ½½¶óÀ̵å´Â 15¸Å À̳», 1Àå´ç 10ÁÙ À̳»·Î Á¦ÀÛÀ» ±ÇÀåÇÔ
    - ÁöÁ¤µÈ ¹ßÇ¥½Ã°£(7ºÐ ¹ßÇ¥, 3ºÐ ÁúÀÇÀÀ´ä ÃÑ 10ºÐ)À» ÁؼöÇÏ¿©¾ß ÇÔ
    - ¹ßÇ¥´çÀÏ 4Ãþ Preview Room¿¡¼­ ÃÖÁ¾ ¹ßÇ¥ÆÄÀÏÀ» È®ÀÎÇϰųª ¼öÁ¤ÆÄÀÏÀ» Á¦Ãâ°¡´É
    (»çÀü Á¦ÃâÀÚ·á¿¡¼­ º¯°æÀÌ ¾ø´õ¶óµµ È®ÀÎÇÏ¿©¾ß Çϸç, ƯÈ÷ µ¿¿µ»óÀ» »ç¿ëÇÏ´Â °æ¿ì¿¡´Â È®ÀÎÇʼö)
¸ðüžÆÀÇÇР  /    »ý½Ä³»ºÐºñÇР  /    ºÎÀÎÁ¾¾çÇР  /    ÀϹݺÎÀΰúÇÐ
ÀϹݿ¬Á¦ : ºÎÀÎÁ¾¾çÇÐ - ÀϽà : 2015³â 9¿ù 18ÀÏ (±Ý)
- Àå¼Ò : ¿¡¸Þ¶öµåȦ B[3F]
GO1-GO4 (08:20~09:00) ÁÂÀå : À̳«¿ì(°í·ÁÀÇ´ë)
GO108:20~08:30 ¼Õ±Ý¼±
¿¬¼¼ÀÇ´ë °­³²¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Expanding Biospecimens from Korean Gynecologic Cancer Bank: Construction of Tissue Micro Arrays and Establishment of Immortalize Cell line.
GO208:30~08:40 º¯½Â¿ø
°¡Å縯ÀÇ´ë ÀÇÁ¤ºÎ¼º¸ðº´¿ø »êºÎÀΰú
¾ÈÁ©¸®³ª Á¹¸®ÀÇ °áÁ¤ÀÌÈÄ BRCA mutation °Ë»ç ¹× ¿¹¹æÄ¡·á¿¡ ´ëÇÑ ÀνÄÁ¶»ç
GO308:40~08:50 ÇÑ°æÈñ
¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú
Residual ascites after neoadjuvant chemotherapy decreases treatment response and survival in patients with advanced-stage epithelial ovarian cancer
GO408:50~09:00 ±è¿µÅÂ
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
The role of re-exploration in uterine sarcoma found incidentally after initial surgery for presumed benign disease
GO5-GO8 (09:00~09:40) ÁÂÀå : ¹®Çý¼º(ÀÌÈ­ÀÇ´ë)
GO509:00~09:10 ±è¿µÅÂ
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
A scoring system to predict the risk of uterine sarcoma in patients with a uterine mass
GO609:10~09:20 ÇãÀºÁø
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
IGFBP5-derived peptide as a novel angiogenesis inhibitor for treatment of ovarian cancer
GO709:20~09:30 ¹ÚÈ¿°æ
¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú
Transvaginal ultrasound-guided biopsy of adnexal masses as a useful diagnostic alternative replacing cytology or laparoscopy in advanced ovarian cancer patients
GO809:30~09:40 ¹éÀ̼±
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma
GO9-GO12 (09:40~10:20) ÁÂÀå : ÀÌÁ¾ÇÐ(°æ»óÀÇ´ë)
GO909:40~09:50 ±è¼±¾Æ
The prevalence of HPV infection in the semen among Korean men and the effect of HPV infection on sperm parameters
GO1009:50~10:00 ÀÌ»óÈÆ
°í·ÁÀÇ´ë ¾È¾Ïº´¿ø »êºÎÀΰú
Validation of an algorithm in Korean Women Ages 21-24 years with either Atypical Squamous Cells of Undetermined Significance or Low-grade Squamous Intraepithelial Lesion
GO1110:00~10:10 À±°Ç
¾ç»êºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú
Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer
GO1210:10~10:20 À¯¼ÒÀº
The risk factors and rate for progression of cervical intraepithelial lesions in HPV 16 or 18 infected women with ASCUS or LSIL: The Korean HPV cohort study.
GO13-GO17 (10:50~11:40) ÁÂÀå : ±èÀçÈÆ(¿¬¼¼ÀÇ´ë)
GO1310:50~11:00 ±èÇöÁ¤
°Ç±¹´ëÇб³º´¿ø »êºÎÀΰú
The impact of positive peritoneal cytology on prognosis in patients with cervical cancer: A meta-analysis
GO1411:00~11:10 ÃÖÀ±Áø
°¡Å縯ÀÇ´ë ¼­¿ï¼º¸ðº´¿ø »êºÎÀΰú
FROM CERVICAL INTRAEPITHELIAL NEOPLASIA TO CERVICAL SQUAMOUS CELL CARCINOMA: AN INTEGRATIVE GENOMIC ANALYSIS
GO1511:10~11:20 ±èÅÂÈÆ
¿øÀÚ·ÂÀÇÇпø »êºÎÀΰú
Outcome of salvage treatment for patients with recurrent cervical cancer; a single institutional cohort study.
GO1611:20~11:30 ¼ÛÀçÀ±
°í·ÁÀÇ´ë ¾È¾Ïº´¿ø »êºÎÀΰú
Role of p16, p63, Ki67 in a two-tier system of low-grade and high-grade squamous intraepithelial lesion
GO1711:30~11:40 ¾ç¿ì°â
¿¬¼¼ÀÇ´ë °­³²¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Application of oncothermia using LabEHY-100 inhibits the growth of ovarian and cervical cancer cells.
GO18-GO21 (11:40~12:30) ÁÂÀå : ¹ÚÁø¿Ï(´Ü±¹ÀÇ´ë)
GO1811:40~11:50 µ¿¸Þ¾Æ¸®
°Ç±¹´ëÇб³º´¿ø »êºÎÀΰú
Impact of surgical staging on prognosis in patients with borderline ovarian tumors: a meta-analysis
GO1911:50~12:00 À±Á¤¿ø
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Role of diagnostic laparoscopy in advanced epithelial ovarian cancer : An experience at a single institution
GO2012:00~12:10 À±°¡¿µ
ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú
Expression of interactive genes associated with apoptosis and their prognostic value for ovarian carcinoma
GO2112:10~12:20 Á¤À±Áö
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Identifying association between obesity and ovarian cancer based on SRA-1 gene over-expression
GO22-GO24 (13:40~14:10) ÁÂÀå : °í¼®ºÀ(´ë±¸°¡Å縯ÀÇ´ë)
GO2213:40~13:50 À̹æÇö
¼­¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú
Efficacy of On-Q Pain Relief System for Postoperative Pain Management in Gynecologic Oncology Patients: A pilot study
GO2313:50~14:00 ±è¹Ì¼±
¼­¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú
Identifying risk factors for CT-based diagnosed post-lymphadenectomy lower-extremity lymphedema in patients with gynecologic cancers
GO2414:00~14:10 ½Å¼¼ÀÎ
°¡Å縯ÀÇ´ë ¼­¿ï¼º¸ðº´¿ø »êºÎÀΰú
Transcriptome analysis reveals that Müllerian inhibiting substance regulates signaling pathways that contribue to endometrial carcinogenesis
ÀϹݿ¬Á¦ : ºÎÀÎÁ¾¾çÇÐ - ÀϽà : 2015³â 9¿ù 18ÀÏ (±Ý)
- Àå¼Ò : ´ÙÀ̾ƸóµåȦ[3F]
GO25-GO28 (15:10~15:50) ÁÂÀå : À̼±°æ(°æÈñÀÇ´ë)
GO2515:10~15:20 ¹ÚÁöÀº
Ä¥°î°æºÏ´ëÇб³º´¿ø »êºÎÀΰú
Prognostic value of F-18 PET metabolic parameters of regional lymph node in locally advanced cervical cancer patients treated with concurrent chemoradiotherapy
GO2615:20~15:30 ³²¼¼Çö
¼º±Õ°üÀÇ´ë °­ºÏ»ï¼ºº´¿ø »êºÎÀΰú
Efficacy of TachoSil¢ç in preventing hemorrhage after loop electrosurgical excision procedure
GO2715:30~15:40 Á¤À¯¿¬
°¡Å縯ÀÇ´ë ¼ººó¼¾Æ®º´¿ø »êºÎÀΰú
Clipping during distal external iliac lymphadenectomy increases lower leg lymphedema in patients with carcinoma of the cervix
GO2815:40~15:50 µµ¾Æ¿µ
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Prognostic factors affected survival outcome of recurrent cervical cancer patients with pulmonary metastases without other organs involvement
GO29-GO31 (15:50~16:20) ÁÂÀå : Á¤ÀºÈ¯(ÃæºÏÀÇ´ë)
GO2915:50~16:00 À̵ÎÇà
¼º±Õ°üÀÇ´ë °­ºÏ»ï¼ºº´¿ø »êºÎÀΰú
Effect of menstrual phase on the surgical treatment of ovarian cyst
GO3016:00~16:10 À̼¼¿¬
Â÷ÀÇ°úÇдëÇб³ ºÐ´çÂ÷º´¿ø »êºÎÀΰú
Oncologic and obstetric outcomes of conservative surgery for borderline ovarian tumor at reproductive age
GO3116:10~16:20 Á¤ÀºÁÖ
¿ï»ê´ëÇб³º´¿ø »êºÎÀΰú
Frequency of a non-rising increase of serum CA-125 levels during chemotherapy treatment in recurrent patients of advanced epithelial ovarian cancer (EOC) after reviously being treated optimally